Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70

NCT00104689 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00104689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
January 31, 2008
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer